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INTRODUCTION
Acute tumor lysis syndrome (ATLS) is observed 
in  a  well-defined  group  of  patients  with  rapidly 
proliferating malignancies and results in the destruction 
and lysis of malignant cells. Lysis of cells results in the 
subsequent release of intracellular ions and metabolites 
into the bloodstream, thus leading to hyperkalemia, 
hyperphosphatemia, hyperuricemia, and hypocalcemia. 
This syndrome occurs either as a consequence of diverse 
anticancer treatments or, less frequently, spontaneously.1 
Although most patients with ATLS are asymptomatic, acute 
renal failure (ARF), metabolic acidosis, life-threatening 
electrolyte abnormalities, cardiac arrhythmias, or seizures 
may accompany the syndrome, thereby increasing the risk 
of associated death.1, 2
Systemic inflammatory response syndrome (SIRS) 
is a pathologic reaction triggered by a variety of insults, 
including infection, trauma, burns, and acute pancreatitis.3 
SIRS becomes more severe when it is complicated by 
organ dysfunction. SIRS-like syndromes have been 
reported in patients with hematologic tumors, which 
reflects rapid cytoreduction.4 SIRS and multiple organ 
dysfunctions (MOD) associated with ATLS would seem 
to be physiologically plausible; however, no study has 
addressed this issue to the best of our knowledge. In this 
manuscript, we report five patients who developed ATLS 
associated with SIRS and MOD in the absence of clear 
alternative explanations.
PATIENTS AND METHODS 
Design and Setting 
This retrospective study was performed at a tertiary 
care public hospital that houses a ten-bed intensive care 
unit (ICU) exclusively for oncology patients, the majority 
of whom are referred to the center from outside hospitals. 
Information about the oncology ICU has been previously 
reported.5 The institutional review board approved this 
study.
From May 2000 to May 2006, the charts of every patient 
admitted to the ICU with a proven diagnosis of ATLS2 were 
reviewed. Demographic, clinical, and laboratory data were 
collected, including the Simplified Acute Physiology Score 
(SAPS) II6 and the Sequential Organ Failure Assessment 
(SOFA) score.7 MOD was defined as the simultaneous 
presence of > 2 organ failures (SOFA score > 2 points for 
each system). SIRS and sepsis were diagnosed using the 
definitions established by the American College of Chest 
Physicians/Society of Critical Care Medicine consensus 
conferences.3 The criteria used for diagnosis of infection 
were those from the Centers for Disease Control.8 
RESULTS 
During the study period, 18 patients presenting with 
ATLS were identified, and MOD occurred in 11 (61%) of 
these patients. Out of these 11 patients, 6 male patients with 
an average age of 52 years (range: 26-61) presented with a 
clinically proven infection, and five developed MOD in the 
absence of an additional definitive cause other than ATLS 
(secondary to infection). These five patients comprised the 
study population. Three of these patients had hematological 
malignancies (high-grade non-Hodgkin’s lymphoma, n=1; 480
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chronic lymphocytic leukemia, n=2), and two patients 
had been diagnosed with solid tumors (germ cell tumor, 
n=1; renal cancer, n=1). The most frequently observed 
comorbidities included the following: thromboembolic 
disease (n=2), hypertension (n=1), diabetes (n=1), and 
malnourishment (n=1). Patients also presented with 
hyperleukocytosis (n=1) or bulky/metastatic disease (n=4). 
The primary risk factors for ATLS and significant laboratory 
alterations are shown in Table 1.
ATLS occurred spontaneously in two patients with 
diffuse large B-cell non-Hodgkin’s lymphoma. In patients 
with chemotherapy-induced ATLS (n=3), the treatment 
regimens included sunitinib for renal cancer, cisplatin and 
etoposide for a germ cell tumor, and cyclophosphamide and 
corticosteroids for chronic lymphocytic leukemia. 
All patients fulfilled the criteria for SIRS on presentation 
to the ICU and had at least three distinct organ dysfunctions 
(Table 1). High levels of C-reactive protein (reference value 
<0.5 mg/dL) were observed in all patients, and the median 
leukocyte count was 14.9 (range = 13.4 - 644.0) x 103 cells/
mm3. The average SAPS II score was 58 (range = 32-66) 
points, and the SOFA score was 11 (range = 5-18) points. 
All patients required ventilatory support; conventional 
mechanical ventilation was used in four patients, while 
non-invasive ventilation was used in one patient. Four 
patients received renal replacement therapy. Routine cultures 
obtained at clinical presentation were either negative (n=4) 
or revealed non-pathogenic bacteria (Streptococcus viridans 
was isolated from a tracheal aspirate of one patient). 
Antibiotics were started empirically in three patients and 
were suspended after a course of three to seven days based 
on negative cultures results and a lack of an apparent 
infection site. Two patients died in the ICU as a consequence 
of MOD. Of the three surviving patients, two did not receive 
antibiotics. Full recovery of renal function was observed in 
two of the surviving patients.
DISCUSSION 
In this study, we describe a series of patients with 
hematologic malignancies and solid tumors who presented 
with ATLS, SIRS, and MOD. Despite extensive diagnostic 
evaluations, neither a source of infection nor any other 
apparent reason for SIRS (including chemotherapeutic 
agents) was found in any of the patients.
Although ATLS typically occurs more frequently in 
patients with hematologic malignancies, it is thought 
that the availability of new and more effective anticancer 
therapies may result in an increased incidence of ATLS 
in patients with solid tumors. Pulmonary dysfunction and 
shock/hypotension have also been described in patients with 
hematologic tumors with intense cell lysis (especially the 
myelomonocytic subtype of acute myeloid leukemia).4 An 
extensive list of clinical manifestations has been described 
in patients with ATLS; however, SIRS was not included in 
this repertoire until now.1,2 
Although the etiology of SIRS in the patients described 
is not fully understood, it is reasonable to hypothesize that 
substances released by the cells during lysis may induce 
severe SIRS. A complex cascade of cytokines has been 
implicated in the development of SIRS, and this phenomenon 
has been well described.9 Pro-inflammatory cytokines 
released by cell lysis may promote nitric oxide-mediated 
vasodilation and alveolar inflammation, which result in 
hypotension and lung injury, respectively. Other substances, 
such as arachidonic acid metabolites and reactive oxygen 
species (ROS), may also induce severe inflammation. In a 
systemic inflammatory response, both endothelial cells and 
neutrophils are activated and release ROS.10 In this setting, 
Table 1 - Main clinical characteristics and laboratory abnor-
malities (n=5)
Characteristics
Risk factors for tumor lysis syndrome
   Large volume of tumor cells * 5
   Azotemia 3
   Lactate dehydrogenase >1500UI/L 1
Laboratory abnormalities
   Hyperkalemia 5
   Hyperuricemia 4
   Metabolic acidosis 4
   Hyperphosphatemia 3
   Hypocalcemia 2
   C-reactive protein (mg/dL) 14.4 (1.62-36.7)
SIRS criteria
   Temperature criteria 2
   Heart rate > 90 bpm 3
   Respiratory rate > 20 or pCO2< 32 mmHg 5
   Leukocyte count criteria 5
Organ Failures
   Respiratory 5
   Renal 5
   Circulatory 3
   Hepatic 3
   Hematological 2
   Neurological 0
* Hyperleukocytosis or bulky disease; SIRS = systemic inflammatory 
response syndrome481
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ROS may perpetuate and augment the systemic inflammation 
and promote organ dysfunction. Moreover, serum uric acid 
is a potent free-radical scavenger and increases in response 
to oxidative stress.11 The majority (4/5) of our patients 
demonstrated high levels of acid uric, and only one patient 
had a prior history of hyperuricemia. Urate crystals may also 
activate proinflammatory pathways and induce a systemic 
inflammatory response.11 In the present study, C-reactive 
protein levels, a surrogate marker of systemic inflammation, 
were elevated in all patients. 
It should be emphasized that the differentiation between 
non-infectious SIRS and sepsis is quite difficult. A lack of 
microbiologic identification in cultures is not equivalent 
to the absence of infection; in addition, the absence of 
viral infections was not systematically determined in these 
patients. Although two out of three of the surviving patients 
did not receive antibiotics, thus corroborating the association 
of ATLS with the development of SIRS and MOD, 
antibiotics should always be given urgently if the presence of 
infection is uncertain until it may be ruled out; this treatment 
strategy was the case for three of our patients.
Potential limitations of our study also include its 
retrospective design and small sample size. We acknowledge 
that the rare occurrence of these severe events lends some 
difficulty to studying the phenomenon in a larger population.4 
Also, the lack of data on plasma levels of procalcitonin and 
pro-inflammatory cytokines is another potential weakness of 
the study. However, although the information is nonspecific, 
we believe that the C-reactive protein levels provided some 
insight to the systemic inflammatory status of the patient 
because they correlate closely with circulating IL-6 levels.12 
In summary, although the present study cannot establish a 
definite causal relationship between ATLS and SRIRS/MOD, 
we have demonstrated that ATLS may present in association 
with SIRS and MOD, the combination of which results in 
significant mortality. It is important that clinicians are aware 
of this life-threatening complication in order to effectively 
implement early interventions and organ support.
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